GOSS · Gossamer Bio Inc. Common Stock
View on chartInsiders & Stakes
| Faheem Hasnain President & CEO | ▲ Buy | Grant | 837,793 Shares held | 1/2/2026 | View profile |
| Christian Waage Director | ▲ Buy | Grant | 814,061 Shares held | 1/2/2026 | View profile |
| Aranda Richard Chief Medical Officer | ▲ Buy | Grant | 463,106 Shares held | 1/2/2026 | View profile |
| Bryan Giraudo Director | ▲ Buy | Grant | 389,737 Shares held | 1/2/2026 | View profile |
| Smith Robert Paul JR Chief Commercial Officer | ▲ Buy | Grant | 260,898 Shares held | 1/2/2026 | View profile |
| Peterson Caryn EVP, Regulatory Affairs | ▲ Buy | Grant | 259,333 Shares held | 1/2/2026 | View profile |
| Carter Laura Chief Scientific Officer | ▼ Sell | Open Market | 76,263 Shares held | 3/16/2023 | View profile |
| Milligan Sandra Director | ▲ Buy | Open Market | 58,050 Shares held | 8/19/2025 | View profile |
Transaction History
| Peterson Caryn | ▲ Buy | Grant | 84,500 | $0 | 1/2/2026 |
| Faheem Hasnain | ▲ Buy | Grant | 280,000 | $0 | 1/2/2026 |
| Bryan Giraudo | ▲ Buy | Grant | 115,750 | $0 | 1/2/2026 |
| Smith Robert Paul JR | ▲ Buy | Grant | 93,750 | $0 | 1/2/2026 |
| Aranda Richard | ▲ Buy | Grant | 93,750 | $0 | 1/2/2026 |
| Christian Waage | ▲ Buy | Grant | 84,500 | $0 | 1/2/2026 |
| Christian Waage | ▲ Buy | Grant | 125,000 | $0 | 10/1/2025 |
| Bryan Giraudo | ▲ Buy | Grant | 181,250 | $0 | 10/1/2025 |
| Aranda Richard | ▲ Buy | Grant | 162,500 | $0 | 10/1/2025 |
| Peterson Caryn | ▲ Buy | Grant | 125,000 | $0 | 10/1/2025 |
| Faheem Hasnain | ▲ Buy | Grant | 437,500 | $0 | 10/1/2025 |
| Smith Robert Paul JR | ▲ Buy | Grant | 162,500 | $0 | 10/1/2025 |
| Milligan Sandra | ▲ Buy | Open Market | 26,050 | $50K | 8/19/2025 |
| Aranda Richard | ▼ Sell | Open Market | 1,908 | $1K | 6/24/2024 |
| Faheem Hasnain | ▲ Buy | Open Market | 372,000 | $250K | 6/21/2024 |
| Bryan Giraudo | ▲ Buy | Open Market | 100,000 | $59K | 6/18/2024 |
| Smith Robert Paul JR | ▲ Buy | Open Market | 25,000 | $15K | 6/17/2024 |
| Christian Waage | ▼ Sell | Open Market | 6,430 | $7K | 3/27/2024 |
| Bryan Giraudo | ▼ Sell | Open Market | 6,430 | $7K | 3/27/2024 |
| Faheem Hasnain | ▼ Sell | Open Market | 23,172 | $27K | 3/27/2024 |
| Aranda Richard | ▼ Sell | Open Market | 4,018 | $5K | 3/18/2024 |
| Peterson Caryn | ▼ Sell | Open Market | 4,018 | $5K | 3/18/2024 |
| Milligan Sandra | ▲ Buy | Open Market | 32,000 | $25K | 11/15/2023 |
| Bryan Giraudo | ▲ Buy | Open Market | 200,000 | $113K | 11/13/2023 |
| Bryan Giraudo | ▲ Buy | Grant | 54,020 | $98K | 7/24/2023 |
| Faheem Hasnain | ▲ Buy | Grant | 540,176 | $983K | 7/24/2023 |
| Christian Waage | ▲ Buy | Grant | 13,504 | $25K | 7/24/2023 |
| Aranda Richard | ▼ Sell | Open Market | 1,814 | $2K | 6/22/2023 |
| Bryan Giraudo | ▲ Buy | Open Market | 55,000 | $56K | 4/4/2023 |
| Faheem Hasnain | ▲ Buy | Open Market | 440,500 | $504K | 3/22/2023 |
| Faheem Hasnain | ▲ Buy | Open Market | 269,389 | $322K | 3/21/2023 |
| Christian Waage | ▲ Buy | Open Market | 18,500 | $22K | 3/20/2023 |
| Bryan Giraudo | ▲ Buy | Open Market | 50,000 | $48K | 3/20/2023 |
| Faheem Hasnain | ▲ Buy | Open Market | 168,683 | $174K | 3/20/2023 |
| Aranda Richard | ▼ Sell | Open Market | 7,563 | $8K | 3/16/2023 |
| Carter Laura | ▼ Sell | Open Market | 6,029 | $7K | 3/16/2023 |
| Peterson Caryn | ▼ Sell | Open Market | 7,564 | $8K | 3/16/2023 |
| Peterson Caryn | ▼ Sell | Open Market | 4,757 | $57K | 10/24/2022 |
| Carter Laura | ▼ Sell | Open Market | 4,876 | $59K | 10/24/2022 |
| Aranda Richard | ▼ Sell | Open Market | 4,757 | $57K | 10/24/2022 |
| Christian Waage | ▲ Buy | Open Market | 6,934 | $50K | 7/15/2022 |
| Bryan Giraudo | ▲ Buy | Open Market | 13,869 | $100K | 7/15/2022 |
| Faheem Hasnain | ▲ Buy | Open Market | 138,696 | $1000K | 7/15/2022 |
| Carter Laura | ▲ Buy | Open Market | 6,934 | $50K | 7/15/2022 |
| Carter Laura | ▼ Sell | Open Market | 8,808 | $73K | 7/1/2022 |
| Aranda Richard | ▼ Sell | Open Market | 1,778 | $12K | 6/22/2022 |
| Carter Laura | ▼ Sell | Open Market | 1,262 | $9K | 5/4/2022 |
| Christian Waage | ▼ Sell | Open Market | 10,722 | $96K | 3/23/2022 |
| Faheem Hasnain | ▼ Sell | Open Market | 19,035 | $170K | 3/23/2022 |
| Bryan Giraudo | ▼ Sell | Open Market | 10,722 | $96K | 3/23/2022 |
| Carter Laura | ▼ Sell | Open Market | 5,002 | $41K | 3/16/2022 |
| Peterson Caryn | ▼ Sell | Open Market | 6,279 | $52K | 3/16/2022 |
| Aranda Richard | ▼ Sell | Open Market | 6,278 | $52K | 3/16/2022 |
| Carter Laura | ▼ Sell | Open Market | 2,377 | $29K | 10/25/2021 |
| Aranda Richard | ▼ Sell | Open Market | 2,377 | $29K | 10/25/2021 |
| Peterson Caryn | ▼ Sell | Open Market | 2,377 | $29K | 10/25/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
GOSS Submits NDA for Seralutinib in Pulmonary Arterial Hypertension
Gossamer Bio has filed a new drug application with the U.S. FDA for Seralutinib, a treatment aimed at pulmonary arterial hypertension. The filing follows a broader after‑market move in health‑care stocks, with GOSS among the 12 that saw activity Friday. The submission could influence the company’s future regulatory path and investor interest.
GOSS Submits NDA for Seralutinib in Pulmonary Arterial Hypertension. Gossamer Bio has filed a new drug application with the U.S. FDA for Seralutinib, a treatment aimed at pulmonary arterial hypertension. The filing follows a broader after‑market move in health‑care stocks, with GOSS among the 12 that saw activity Friday. The submission could influence the company’s future regulatory path and investor interest.